Insulet (MEX:PODD) DeferredTaxAndRevenue : MXN0 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Insulet DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Insulet's current deferred tax and revenue for the quarter that ended in Mar. 2025 was MXN0 Mil.

Insulet DeferredTaxAndRevenue Historical Data

The historical data trend for Insulet's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet DeferredTaxAndRevenue Chart

Insulet Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

DeferredTaxAndRevenue

Get a 7-Day Free Trial

Insulet Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
DeferredTaxAndRevenue	Get a 7-Day Free Trial															-	-	-	-	-

Insulet DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Insulet's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Insulet Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (MEX:PODD) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

PODD:USA 1PODD:Italy GOV:Germany

Address

100 Nagog Park, Acton, MA, USA, 01720

Website

https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.